LX7101

Modify Date: 2024-01-11 14:58:05

LX7101 Structure
LX7101 structure
Common Name LX7101
CAS Number 1192189-69-7 Molecular Weight 451.52100
Density N/A Boiling Point N/A
Molecular Formula C23H29N7O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of LX7101


LX7101 is a potent inhibitor of LIMK and ROCK2 with IC50 values of 24, 1.6 and 10 nM for LIMK1, LIMK2 and ROCK2, respectively; also inhibits PKA with an IC50 less than 1 nM.

 Names

Name 3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl N.N-dimethylcarbamate
Synonym More Synonyms

 LX7101 Biological Activity

Description LX7101 is a potent inhibitor of LIMK and ROCK2 with IC50 values of 24, 1.6 and 10 nM for LIMK1, LIMK2 and ROCK2, respectively; also inhibits PKA with an IC50 less than 1 nM.
Related Catalog
Target

ROCK2:10 nM (IC50)

LIMK2:1.6 nM (IC50)

LIMK1:24 nM (IC50)

PKA:1 nM (IC50)

In Vitro LX7101 is a dual LIM-kinase and ROCK inhibitor for the treatment of ocular hypertension and associated glaucoma. LX-7101 also displays potent inhibition of Akt1 with an IC50 of less than 1 nM[1]. The overall selectivity of LX7101 for LIMK2 increases at the higher physiological ATP concentrations. Under physiological conditions, the activity of LX7101 is primarily due to inhibition of LIMK2[2].
In Vivo LX-7101 is advanced to Phase-I clinical trials as an intraocular pressure (IOP)-lowering agent for treatment of glaucoma. LX-7101 displays a significant IOP reduction at time points ranging from 1 h to 6 h post administration in rabbits[1]. Topical doses of LX-7101 are evaluated for tolerability on the eyes of mice, rats, and rabbits. It is well tolerated at doses up to 0.5% in non-GLP single dose studies. In the mouse IOP assay, LX-7101 (5%) achieved additional reduction of IOP (5.0 mmHg total reduction) compared to the 0.1% formulation and demonstrated a long duration of action, with IOP not returning to baseline until more than 8 h postdose[2].
References

[1]. Boland S, et al. Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorganic & Medicinal Chemistry Letters (2015), 25(18), 4005-4010.

[2]. Harrison BA, et al. Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma. ACS Medicinal Chemistry Letters (2015), 6(1), 84-88.

 Chemical & Physical Properties

Molecular Formula C23H29N7O3
Molecular Weight 451.52100
Exact Mass 451.23300
PSA 129.47000
LogP 3.34900
Storage condition 2-8℃

 Synonyms

LX7101
3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
3-(4-(aminomethyl)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyldimethylcarbamate
Top Suppliers:I want be here



Get all suppliers and price by the below link:

LX7101 suppliers


Price: $286/10mM*1mLinDMSO

Reference only. check more LX7101 price